| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.43 | 1-year : | 8.68 |
| Resists | First : | 6.36 | Second : | 7.43 |
| Pivot price | 5.45 |
|||
| Supports | First : | 5.43 | Second : | 4.86 |
| MAs | MA(5) : | 5.76 |
MA(20) : | 5.47 |
| MA(100) : | 5.04 |
MA(250) : | 4.79  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 82.5 |
D(3) : | 70.6 |
| RSI | RSI(14): 59.4 |
|||
| 52-week | High : | 7.36 | Low : | 2.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed below upper band by 1.3%. Bollinger Bands are 6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.17 - 6.19 | 6.19 - 6.21 |
| Low: | 5.71 - 5.73 | 5.73 - 5.76 |
| Close: | 6.1 - 6.15 | 6.15 - 6.19 |
Thu, 25 Sep 2025
Next-Gen DMD Gene Therapy Data: Solid Bio's SGT-003 Shows Promising Safety Profile at 90 Days - Stock Titan
Tue, 23 Sep 2025
Cantor Fitzgerald Sticks to Their Buy Rating for Solid Biosciences (SLDB) - The Globe and Mail
Tue, 23 Sep 2025
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating - 富途牛牛
Tue, 23 Sep 2025
Solid Biosciences grants AAV-SLB101 license to Kinea Bio - Seeking Alpha
Tue, 23 Sep 2025
Next-Gen Gene Therapy Capsid with 15 Patient Safety Data: Solid Biosciences Expands Licensing Network - Stock Titan
Thu, 11 Sep 2025
Alyeska Investment Group L.P. Buys 1,294,450 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 78 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 105.9 (%) |
| Shares Short | 9,850 (K) |
| Shares Short P.Month | 10,110 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.4 % |
| Return on Equity (ttm) | -68.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.24 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -123 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -2.21 |
| PEG Ratio | 0 |
| Price to Book value | 1.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|